Lambda IFN 可以抑制HBV和HCV的复制(2005.3.19)

zasxz

Lambda interferon inhibits hepatitis B and C virus replication.

Robek MD, Boyd BS, Chisari FV.

Department of Molecular and Experimental Medicine, The Scripps Research
Institute, La Jolla, California, USA. [email protected]

Lambda interferon (IFN-lambda) induces an intracellular IFN-alpha/beta-like
antiviral response through a receptor complex distinct from the
IFN-alpha/beta receptor. We therefore determined the ability of IFN-lambda
to inhibit hepatitis B virus (HBV) and hepatitis C virus (HCV) replication.
IFN-lambda inhibits HBV replication in a differentiated murine hepatocyte
cell line with kinetics and efficiency similar to IFN-alpha/beta and does
not require the _expression of IFN-alpha/beta or IFN-gamma. Furthermore,
IFN-lambda blocked the replication of a subgenomic and a full-length genomic
HCV replicon in human hepatocyte Huh7 cells. These results suggest the
possibility that IFN-lambda may be therapeutically useful in the treatment
of chronic HBV or HCV infection.

PMID: 15731279 [PubMed - in process]

as100200

Newly Identified Protein May Inhibit Hepatitis Virus

A newly identified family of proteins may inhibit replication of the Hepatitis B (HBV) and C (HCV) viruses say researchers from California. Their findings appear in the March 2005 issue of the Journal of Virology.

Hepatitis B (HBV) and C (HCV) are viruses that infect the liver, and in some cases can cause liver failure requiring a transplant for survival. The protein interferon, produced by animal cells when they are invaded by viruses, is released into the bloodstream or intercellular fluid to induce healthy cells to manufacture an enzyme that counters the infection. One class of interferons (alpha) is used to treat chronic infection with HBV and HCV. There is a vaccine available to prevent the spread of HBV but not HCV.

In the study, a new class of interferons, interferon lambda, was tested for its ability to inhibit HBV and HCV replication. Results showed 90% inhibition of HBV after twenty-four hours and 90-99% inhibition in HCV five days posttreatment.

"We have demonstrated here that replication of HBV and HCV is sensitive to the antiviral activities of interferon lambda," say the researchers. "These results suggest the possibility that interferon lambda may be therapeutically useful in the treatment of chronic HBV or HCV infection."

(M.D. Robek, B.S. Boyd, F.V. Chisari. 2005. Lambda interferon inhibits hepatitis B and C virus replication. Journal of Virology, 79. 6: 3851-3854.)